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Abstract
Cerebral dopamine neurotrophic factor (CDNF) shows beneficial effects in rodent models of Parkinson’s and Alzheimer’s
disease. The brain is a challenging target for protein therapy due to its exclusive blood–brain barrier. Hence, the therapeutic
protein should be delivered directly to the brain parenchyma. Implantation of encapsulated mammalian cells that constantly
secrete CDNF is a potential approach for targeted and long-term protein delivery to the brain. In this study, we generated
several CDNF-secreting cell clones derived from human retinal pigment epithelial cell line ARPE-19, and studied CDNF
secretion from the clones maintained as monolayers and in polymeric microcapsules. The secretion of wild type (wt) CDNF
transgene was low and the majority of the produced protein remained intracellular, locating mainly to the endoplasmic
reticulum (ER). The secretion of wtCDNF decreased to even lower levels when the clones were in a non-dividing state, as in
the microcapsules. Both codon optimization and deletion of the putative ER-retrieval signal (four last amino acids: KTEL)
improved CDNF secretion. More importantly, the secretion of KTEL-deleted CDNF remained constant in the non-dividing
clones. Thus, cells expressing KTEL-deleted CDNF, in contrast to wtCDNF, can be considered for cell encapsulation
applications if the KTEL-deleted CDNF is proven to be biologically active in vivo.
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Introduction
Cerebral dopamine neurotrophic factor (CDNF)1 and its
homolog mesencephalic astrocyte-derived neurotrophic fac-
tor (MANF)2 form a neurotrophic factor family, which dif-
fers structurally, and most probably functionally, from the
classical neurotrophic factor families3. CDNF was first
described as being able to protect and rescue midbrain dopa-
mine neurons in vivo in a rat 6-hydroxydopamine (6-OHDA)
model of Parkinson’s disease when delivered into brain par-
enchyma as a single injection1. Later, the potency of CDNF
to promote the survival and recovery of dopamine neurons
has been verified in the rat 6-OHDA model after continuous
protein infusion4, and viral gene delivery5–7. CDNF has also
been demonstrated to be neuroprotective and neurorestora-
tive after single injection in a mouse 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) model of PD8. The
potential role of CDNF in long-term memory was shown
in a mouse model for Alzheimer’s disease after intrahippo-
campal injections of purified protein or adeno-associated
virus serotype 2 (AAV2)-CDNF9. Both Parkinson’s and Alz-
heimer’s diseases lack restorative therapy.
The central nervous system is surrounded by the blood–
brain barrier, which restricts the diffusion of large hydrophilic
molecules from the blood circulation. Thus, the therapeutic
protein in many cases needs to be delivered directly to the
target site in the brain. This can be achieved by administration
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of the protein by injection or infusion, by gene therapy, or by
the aid of implanted cells secreting the therapeutic protein10.
Therapeutic protein-secreting cells can be enclosed within a
semipermeable membrane, which allows the diffusion of the
protein and nutrients, but restricts host immune rejection. A
device carrying the encapsulated cells is then delivered to the
treatment site. This approach provides constant release of
therapeutically active protein from mammalian cells to the
site of action, but the encapsulated cells can be retrieved if
needed11.
In this study, we sought to generate CDNF-secreting
ARPE-19 cell clones for therapeutic cell encapsulation
purposes. The ARPE-19 cell line was chosen as the par-
ental cell line because of multiple beneficial characteris-
tics in terms of encapsulated cell technology. The cell
line has been shown to endure in alginate microcapsules
for several months in vitro12,13, and it demonstrates
contact-inhibited growth14. This contact-inhibited growth
is important, as continuous cell proliferation could accu-
mulate pressure in the capsule and possibly rupture the
capsule membrane; similarly, it could lead to the necrosis
of the cells, as seen in case of encapsulated fibroblasts11.
The ARPE-19 cell line is of human origin, and it has been
used in clinical cell therapy applications without major
safety concerns15–18.
In contrast to other proteins expressed in the same cell
line for cell encapsulation purposes19,20, we observed poor
secretion of wild type (wt) CDNF transgene from the ARPE-
19 cell clones. We here report the effects of two different
methods employed aiming for improved CDNF expression
and secretion. Firstly, we used codon optimization, where
the codons are changed to represent a more ubiquitous trans-
fer RNA in the host while keeping the resulting amino acid
sequence unchanged21. Secondly, since majority of the pro-
duced wtCDNF remained intracellular, locating mainly to
the endoplasmic reticulum (ER), we studied the effect of
removing the putative C-terminal ER-retrieval signal on
CDNF secretion. The secreted and intracellular CDNF was
quantified by a novel in-house-built enzyme-linked immu-
nosorbent assay (ELISA).
Materials and Methods
Cell Lines
Human retinal pigment epithelial cell line, ARPE-19 (ATCC
number CRL-2302), was cultured in DMEM-F12 (GibcoTM
31330), 10% fetal bovine serum (FBS), 100 U/ml penicillin
and 100 mg/ml streptomycin (all from Thermo Fisher Scien-
tific, Waltham, MA, USA). HeLa (CRM-CCL-2), EA.hy926
(CRL-2922), SH-SY5Y (CRL-2266) and U-87 MG (HTB-14)
cell lines were cultured in DMEM (D7777, Sigma-Aldrich,
Saint Louis, MO, USA), 10% FBS, 100 U/ml penicillin and
100 mg/ml streptomycin. All the cells were cultured in a cell
incubator at 37C and 5% CO2.
Plasmids
Mammalian expression plasmids pCI-neo (Promega, Madi-
son, WI, USA) and pCR3.1 (Invitrogen, Carlsbad, CA, USA)
were used in this study. Both vectors contain CMV-promoter
for the transgene expression and neomycin resistance gene
for clone selection. Human CDNF cDNA in pCR3.1 vector1
was subcloned into pCI-neo vector at restriction sites NheI
and XbaI. Codon-optimized (opti) human CDNF cDNA (in
BV-vector, obtained from Icosagen, Tartu, Estonia) was
amplified by PCR using primers 5’GCTAGCGCCACCATG
TGGTGCGCCTC-3’ and 5’-CCAAGACCGAGCTGTGA-
TAACTCGAG-3’ and inserted into pCR3.1 vector.
To produce plasmids expressing CDNF lacking the puta-
tive ER-retrieval sequence (KTELdel), we performed
inverse PCR mutagenesis on plasmids wtCDNF-pCR3.1 and
optiCDNF-pCR3.1 using primers 5’-GGGGTGTGTCGCTG
CATACT-3’ and 5’-TGATCAAGCCGAATTCTGCA-3’;
and 5’-GGGGTGGGTAGCGGCGTACTTA-3’ and 5’-
TGATAACTCGAGAAGCCGAATTCTGCAG-3’, respec-
tively, with Phusion™ high-fidelity DNA polymerase
(Thermo Fisher Scientific). After the PCR reaction, the plas-
mid template was digested with DpnI treatment (Thermo
Fisher Scientific). PCR products were purified using QIA-
quick PCR Purification Kit (Qiagen, Hilden, Germany), and
phosphorylated with T4 polynucleotide kinase (Thermo
Fisher Scientific) before ligation reaction. After amplifica-
tion in E. coli DH5a cells, plasmids were purified using
QIAGEN Plasmid purification kit (Qiagen). All constructs
were confirmed by sequencing.
Transient and Stable Transfections
For the analysis of transgene expression and secretion under
transient transfection, ARPE-19 cells were transfected with
pCR3.1 vectors encoding either wtCDNF, wtCDNF-
KTELdel, optiCDNF, or optiCDNF-KTELdel with Lipofec-
tamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Samples were collected 48 h post-transfection
and analyzed on CDNF ELISA, by western blotting, and by
immunocytochemistry.
For the production of stable clones, cells were transfected
as stated above, except wtCDNF was in pCI-neo expression
vector. Then, 24 h after transfection, the cells were seeded on
new culture plates at different densities and selection anti-
biotic G418 (at 0.8 mg/ml; Geneticin, Thermo Fisher Scien-
tific) was added 48 h after transfection. The concentration of
G418 was gradually decreased to the maintenance level of
0.4 mg/ml within 4 weeks. During the selection period, cell
colonies originating from single cell were isolated and
expanded.
Protein Samples
Conditioned media from cultured cells were collected, cen-
trifuged 2000 rpm for 5 min at þ4C, and the supernatants
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were collected. Cells were washed twice with phosphate
buffered saline (PBS), and incubated for 30 min in ice-
cold lysis buffer (137 mM NaCl, 20 mM Tris-HCl (pH
8.0), 1% Igepal, 10% glycerol, 2.5 mM EDTA, 0.5 mM
Na3VO4, and protease inhibitors (Complete mini protease
inhibitor cocktail, Roche, Basel, Switzerland)). The lysates
were centrifuged at 12,000 rpm for 20 min at þ4C and the
supernatants were collected. For the measurement of endo-
genous CDNF and MANF, cells were divided on 6-well
plates at concentration of 0.3106 cells/well. The next day,
0.6 ml of growth medium was applied to the cells for 72 h.
After incubation, 0.45 ml of conditioned medium was col-
lected and the cells were subsequently lysed in 0.45 ml of
lysis buffer. For the analysis of protein expression after tran-
sient transfection, cells were incubated in Opti-MEM for 24
h after which the conditioned medium was collected. Cells
were lysed in lysis buffer, using volume equal to that of the
conditioned medium. In case of stable clones, cells were
seeded on 12-well plates at density of 0.4106 cells/well
and 24 h after incubated with 0.5 ml of Opti-MEM or growth
medium for 30 to 60 min. Cells were collected in 0.5 ml of
lysis buffer. Total protein concentration in the cell lysates
was measured using DCTM Protein Assay (Bio-Rad, Her-
cules, CA, USA).
CDNF ELISA
Human CDNF levels in cell lysates and conditioned medium
samples were analyzed by in-house-built CDNF ELISA. In
brief, MaxiSorp (Nunc, Thermo Fisher Scientific) 96-well
plates were coated overnight at þ4C with mouse anti-
human CDNF mAb, clone 7D6 (301-100, Icosagen), at 1
mg/ml in 50 mmol/l carbonate coating buffer (35 mmol/l
sodium bicarbonate, 15 mmol/l sodium carbonate; pH 9.6).
The plate was washed once with PBS/0.05% Tween 20
(PBST) and incubated with blocking buffer (3% BSA
(Probumin® Merck Millipore, Burlington, MA, USA) in
PBS) at RT for 2 h. After washing with PBST, standard
samples of recombinant human CDNF (P-100-100, Icosa-
gen), ranging from 31.25 to 2000 pg/ml, and study samples
diluted in blocking buffer, were added to the plate in dupli-
cate and incubated overnight at þ4C with agitation (100
rpm). The detection antibody, horseradish peroxidase
(HRP)-conjugated mouse anti-human CDNF mAb, clone
6G5 (302-100, Icosagen), was incubated on the plate at a
concentration of 1 mg/ml for 5 h in agitation at RT. Washing
with PBST was repeated four times before and after the
antibody incubation. For detection, 3,3’,5,5’-tetramethyl-
benzidine was used according to the manufacturer’s instruc-
tions (DuoSet ELISA Development System, R&D Systems,
Minneapolis, MN, USA). The absorbance was read using a
plate reader (VICTOR3, Perkin Elmer, Waltham, MA) at 450
nm and 540 nm (for wavelength correction).
Sensitivity of the CDNF ELISA was determined by the
mean response of 10 blank samples added with three stan-
dard deviations (SD). Within the assay dynamic range, the
individual back-calculated accuracy values were within 20%
relative error (RE ¼ derived concentration / expected con-
centration  100%) and precision within 15% coefficient of
variation (CV ¼ SD / mean  100%). Intra-assay variation
was determined by measuring three samples with varying
CDNF concentration in replicates of 10 in different parts
of a plate. Interassay precision was determined by running
same three samples in duplicate in multiple independent
assays. Specificity of the ELISA was tested by measuring
cross reactivity to recombinant mouse CDNF (R&D Sys-
tems) and recombinant human MANF (Icosagen).
MANF ELISA
Endogenous human MANF concentration in the cell samples
was analyzed by an in-lab-built MANF ELISA22 with a sen-
sitivity of 45 pg/ml and 8.1 + 2.1% CV intra-assay and 5.5
+ 1.2% CV interassay reproducibility. The MANF ELISA
does not detect human CDNF.
Western Blotting
Conditioned medium samples were concentrated 20-fold
using Amicon Ultra centrifugal filters with 10 kDa cut off
(UFC501024, Merck Millipore). The concentrated media
and cell lysates were mixed with reducing loading buffer
(containing 5% b-mercaptoethanol as final concentration),
and proteins were denatured by heating at þ95C for 5 min.
Proteins were separated on 15% SDS-PAGE and transferred
on nitrocellulose membrane (0.45 mm, Amersham
HybondTM ECLTM, GE Healthcare, Chicago, IL, USA).
The proteins were detected with rabbit anti-CDNF
(0.4 mg/ml1) and by mouse anti-actin as a loading control
(1:1 000, A-4700, Sigma-Aldrich), followed by HRP-linked
secondary antibody. Signal was visualized using ECL West-
ern Blotting Substrate kit (Thermo Fisher Scientific).
Immunocytochemistry
The parental cells or stable cell clones were seeded on cover-
slips, transfected in case of parental cell line, fixed with 4%
PFA (48 h after transfection), permeabilized with 0.1%
Triton-X and stained with following antibodies: rabbit
anti-CDNF (0.4 mg/ml1), mouse anti-PDI, 1:150 (Enzo Life
Sciences, Farmingdale, NY, USA), or mouse anti-GM130,
1:100 (BD Transduction LaboratoriesTM, Franklin Lakes,
NJ, USA). Secondary antibodies goat anti-rabbit Alexa
568, 1:400), and donkey anti-mouse Alexa 488, 1:400 (both
from Life Technologies, Thermo Scientific) were used for
detection of the corresponding primary antibodies. Nuclei
were stained with Hoechst 3345 (Sigma-Aldrich). Fluores-
cent microscopy images were captured using confocal
microscope (Leica TCS SP5, Wetzlar, Germany), or epi-
fluorescent microscope (Olympus AX 70 Provis, Tokyo,
Japan).
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For immunocytochemistry, following controls were
included: (1) omission of the primary antibodies, for analyz-
ing possible unspecificity of the secondary antibodies used,
and (2) separate single antibody stainings, for analyzing pos-
sible channel leakage. Non-transfected wtARPE-19 cells
stained with the in-house-produced CDNF antibody did not
give background with the light exposure time used (see
Fig. 3b, Results), reflecting low endogenous CDNF levels
and high specificity of the antibody used.
Cell Encapsulation
Encapsulation of cell clones was performed by an in-house-
built microencapsulation device12 using alginate-poly-L-
lysine-alginate (APA) protocol12,13. In brief, cells growing
on culture dishes were detached and suspended in 1.2%
alginate (UP LVG, FP-303-02, NovaMatrix, Sandvika, Nor-
way) at three different cell densities: 2, 4, and 6 million cells/
ml of alginate. The microcapsules were produced by disper-
sing syringe-extruded alginate-cell suspension with nitrogen
gas using a nozzle that allows co-laminar flow. The alginate
was cross-linked with divalent cations by incubating the
capsules first in 68 mM CaCl2 solution (3 min), followed
by incubation in 20 mM BaCl2 solution (5 min). Cross-
linked alginate capsules were incubated in 0.1% poly-L-
lysine solution (15-30 kDa, Sigma-Aldrich) (5 min) for
increased durability. A final coating in 0.125% alginate solu-
tion (5 min) was added to ensure biocompatibility of the
capsules. The capsules produced this way have a molecular
weight cut off at 50 kDa13. Thus, 18 kDa CDNF should be
able to diffuse from the capsules freely.
The average diameter of the produced capsules was deter-
mined from images taken with a digital camera connected to
a phase contrast microscope (Leica). The images were pro-
cessed with LAS EZ program and a minimum of 100 cap-
sules/cell density was analyzed.
Viability of the encapsulated cells was assessed by fluor-
escent LIVE/DEAD staining (Molecular Probes, Thermo
Fisher Scientific) and by Alamar Blue reagent reflecting the
activity of mitochondria (Invitrogen). LIVE/DEAD staining
with calcein/ethidium homodimer-1 was performed 24 h
after cell encapsulation as described earlier for APA-
encapsulated ARPE-19 cells12,13. In the Alamar Blue test,
capsules were incubated with 400 ml of 10% Alamar Blue
reagent for 5 h, after which an aliquot of the incubation
medium was transferred into a black 96-well plate and ana-
lyzed on plate reader (VarioskanTM Flash, Thermo Fisher
Scientific) for fluorescence emission using excitation/
emission wavelengths of 530/590 nm.
CDNF secretion from the encapsulated cells in Opti-
MEM after 6 h incubation was studied by CDNF ELISA.
For Alamar Blue and CDNF secretion studies, capsules were
transferred into 24-well plates and the capsule number in
each well was calculated from pictures taken with Canon
system camera connected to a microscope (Meiji, San Jose,
CA, USA). The results were normalized to the capsule
number in each sample and expressed as mean + SEM of
three parallel samples with >100 microcapsules. Alamar
Blue results are expressed in fluorescence intensity/capsule
and CDNF secretion in pg/100 capsules/24 hours. The
assays were performed at days 1, 4, 7, 14, and 28 after
encapsulation.
Statistics
The data are presented as mean + SEM. Differences
between two related groups were analyzed by paired samples
t-test. Differences between three or more groups were ana-
lyzed by one-way analysis of variance (ANOVA), followed
by Dunnett’s post hoc test. Multiple timepoints were com-
pared by repeated measures ANOVA with Bonferroni’s cor-
rection. A p-value of less than 0.05 was considered
statistically significant. Statistical analysis was performed
using IBM SPSS software.
Results
Characterization of Human CDNF ELISA
Sensitivity of the in-lab-built mAb human CDNF ELISA was
30.5 pg/ml, and dynamic range was 31.25–2 000 pg/ml. Aver-
age intra- and interassay variations were 7.1% coefficient of
variation, CV (range 6.4–8.6), and 8.8% CV (5.5–11.2),
respectively. The assay did not detect mouse CDNF nor
human MANF (highest tested concentration was 500 ng/
ml). The ELISA recognized KTEL-deleted human CDNF as
well as wtCDNF. As the antibodies used in the ELISA are
monoclonal, the detection of both wtCDNF and KTEL-
deleted CDNF should be equal.
Endogenous CDNF is not Found in the Conditioned
Medium
Five human cell lines were studied for secreted endogenous
CDNF in the culture media: epithelial-like ARPE-19 and
HeLa, endothelial-like EA.hy926, neuronal-like SH-SY5Y,
and glial-like U-78 MG. In all cases, CDNF remained under
the detection limit (<30.5 pg/ml) in the conditioned media of
dividing cells at 72 h (Table 1). Instead, MANF was found in
the media of all the studied cell lines at concentrations rang-
ing from 0.41 to 4.20 ng/ml. In the cell lysates, MANF was
found at 160 to 230 times higher concentrations compared
with CDNF. CDNF concentration in cell lysate was 0.36 to
0.73 ng/ml, whereas MANF was found at levels from 57.2 to
128.3 ng/ml.
High Concentration of Intracellular wtCDNF in
ARPE-19 Clones
Several wtCDNF-expressing and secreting ARPE-19 cell
clones were isolated after transfection of the parental cell
line with pCI-neo vector carrying CDNF cDNA sequence
under a CMV-promoter, and neomycin phosphotransferase
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gene for selection. Endogenous CDNF concentration in the
parental ARPE-19 cell lysate, representing the intracellular and
possibly membrane-bound CDNF, was 0.28 + 0.01 ng/mg
total protein (mean + SEM, n¼4). Differently from the par-
ental cell line, intracellular CDNF concentration in four tested
ARPE-19 cell clones expressing and secreting wtCDNF ranged
from 95.9+ 2.9 to 508.3+ 25.1 ng/mg (n¼ 2–3/clone). This
means that the intracellular CDNF concentration in the clones
was increased up to 1800-fold compared with the parental cell
line (p¼0.001–0.007, one-way ANOVAþDunnett’s test, Fig.
1a). Strong co-localization of CDNF and the ER-resident
enzyme PDI was found by confocal microscopy of immuno-
fluorescent double-labeled cells, indicating that intracellular
CDNF mainly resided in the ER in the wtCDNF ARPE-19
clones (Fig. 1b).
Secretion of wtCDNF is Inhibited When the Cells are
Confluent
Average CDNF secretion from the wtCDNF ARPE-19
clones was 0.48+ 0.08 ng/0.4106 cells/30 min (min–max:
0.02–0.85 ng/0.4106 cells/30 min, depending on the clone,
n¼12). CDNF secretion decreased when cell clones reached
confluence. The average CDNF medium concentration in
cultures held for 14 days without sub-cultivation was only
18.5 + 4.4% (min–max: 3.3–46.3%) from the initial
(p<0.001, paired samples t-test, n¼11).
Differently from secreted CDNF, intracellular CDNF
concentration did not decrease in the confluent wtCDNF
ARPE-19 cultures. Cells growing for 14 days without sub-
cultivation had intracellular CDNF concentration of 114.7
+ 17.1% from that of parallel cultures subcultivated 1:2 1
day before sample collection (p¼0.79, paired samples t-test,
n¼5 clones). Thus, the observed drop in CDNF secretion
from the clones in confluent state seems not to be caused
by decreased CDNF synthesis, but rather decreased secretion
in the non-dividing cells. One day after sub-cultivation of
confluent cultures, CDNF concentration in the medium was
54.3 + 13.8% from the initial. In the parallel samples held
without sub-cultivation, CDNF medium concentration was
21.2 + 5.7% from the initial (p¼0.036, paired samples
t-test, n¼6) (Fig. 1c), indicating that the secretion of CDNF
can be re-induced in the cells after sub-cultivation.
Good Cell Viability, but Poor wtCDNF Secretion from
the Encapsulated Cells
Cell clones were encapsulated in alginate at three differ-
ent cell densities: 2, 4, and 6 million cells/ml of alginate.
An image taken on an inverted phase microscope of the
capsules is shown in Fig. 2a. The mean diameter of the
produced microcapsules was 169 + 32, 161 + 22, and
179 + 23 mm for 2, 4, and 6 million cells/ml alginate,
respectively. Mean diameter of all microcapsules was
169 + 26 mm (range 99–222 mm, Fig. 2b). Staining with
LIVE/DEAD kit showed that the cells endured the encap-
sulation well, as only a few dead cells were detected (Fig.
2c). Analysis with Alamar Blue reagent showed steady
metabolic function of the encapsulated cells up to 28
days, which was the duration of analysis (Fig. 2d).
CDNF was found in the conditioned media of encapsulated
cells. Secreted CDNF amount was dependent on the cell den-
sity in the capsules (Fig. 2e). Four days after encapsulation,
CDNF secretion was at its peak. At this time point, CDNF was
secreted into the media at levels of 71 + 14, 248 + 68, or
644+ 43 pg/100 capsules/24 h (n¼3 replicates/group), in the
case of cell encapsulation densities of 2, 4, and 6 million
cells/ml, respectively. CDNF secretion decreased close to
zero within 28 days from capsulation.
Improved CDNF Secretion with Codon-Optimized
CDNF and KTEL Deletion
Since wtCDNF secretion was low, we studied the effects of
codon optimization, deletion of the putative ER-retrieval sig-
nal, and their combination to improve CDNF secretion from
the cells. After transient transfection of wtCDNF-pCR3.1 to
ARPE-19 cells, only 8% of the total cellular wtCDNF was
secreted within 24 h. Codon optimization resulted in a 3-fold
increase in the secreted CDNF concentration, as shown by
transient transfection of optiCDNF-pCR3.1 (Fig. 3a, Table 2).
The intracellular CDNF concentration was almost doubled in
Table 1. Endogenous CDNF and MANF Protein Concentrations in Cell Lysates and Conditioned Media of Selected Cell Lines of Human
Origin. Results are Shown as Average + SEM (n¼3).
Human cell line ARPE-19 HeLa EA.hy926 SH-SY5Y U-87 MG
MANF
Conditioned medium (ng/ml) 0.41 + 0.03 3.99 + 0.07 2.15 + 0.16 1.27 + 0.08 4.20 + 0.46
Cell lysate (ng/ml) 91.7 + 2.1 128.3 + 2.4 57.2 + 2.7 85.3 + 1.1 70.5 + 2.2
% secreted 0.4 3.0 3.6 1.5 5.6
CDNF (ng/ml)
Conditioned medium (ng/ml) n.d. n.d. n.d. n.d. n.d.
Cell lysate (ng/ml) 0.49 + 0.02 0.73 + 0.03 0.36 + 0.01 0.37 + 0.01 0.43 + 0.02
% secreted n.a. n.a. n.a. n.a. n.a.
MANF vs. CDNF in cell lysate (times) 187 176 159 231 164
n.d. ¼ not detected, n.a. ¼ not applicable.
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the cells transfected with optiCDNF compared with wtCDNF.
Thus, the increase in CDNF concentration in the medium is
rather due to the increased CDNF expression by codon opti-
mization than improved secretion.
CDNF secretion from cells transfected with wtCDNF-
KTELdel was approximately three times higher compared
with cells transfected with the wtCDNF, but the intracellular
CDNF concentration of wtCDNF-KTELdel cells was only
30% from that of wtCDNF transfected cells (Fig. 3a, Table
2). This implies that the change seen in CDNF medium
concentration after KTEL deletion was a consequence of
improved secretion and not due to differential CDNF expres-
sion. The immunofluorescence images of transiently trans-
fected cells expressing KTEL-deleted CDNF showed
Figure 1. High levels of intracellular CDNF, which localize to the ER in the stable wtCDNF ARPE-19 cell clones. (a) Intracellular CDNF
concentration in the clones ranged from 95.9+ 2.9 to 508.3+ 25.1 ng/mg (mean+ SEM, n¼2–3/clone), whereas, in the parenteral ARPE-
19 cell line it was 0.28+ 0.01 ng/mg total protein (n¼4). The increase in the clone intracellular CDNF concentration was up to 1800-fold
compared with the parenteral cell line (p¼0.001–0.007, one-way ANOVA þ Dunnett’s test). (b) Immunofluorescent image of a wtCDNF
ARPE-19 cell clone double stained to show the ER (PDI, green) and CDNF (red) and imaged by confocal microscopy. Merged image shows
co-localization of CDNF and ER-marker (yellow). (c) CDNF secretion decreased down to 21.2+ 5.7% from the initial secretion when the
wtCDNF ARPE-19 clones were held without sub-cultivation for 14 days. Parallel to non-subcultivated, the same clones were subcultivated
1:2 on day 13 and CDNF secretion was analyzed at day 14. In the subcultivated cells CDNF secretion was 54.3 + 13.8% from the initial
secretion (p¼0.036, paired samples t-test, n¼6). ** p<0.01, * p<0.05.
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different staining patterns with CDNF antibody compared
with cells expressing wtCDNF (Fig. 3b). Epifluorescence
microscope images showed some co-localization of the
KTEL-deleted CDNF with a Golgi marker GM130. This
contrasts wtCDNF that colocalized only with the ER marker
PDI.
Combination of KTEL deletion and codon optimization
resulted in 5-fold increased CDNF secretion compared with
that of wtCDNF. Intracellular concentration of optiCDNF-
KTELdel was only 20% of that seen for codon-optimized
CDNF, implying that KTEL deletion again increased secre-
tion of CDNF.
Secretion of KTEL-Deleted Codon-Optimized CDNF is
Stable in 2D Cultures
Stable ARPE-19 cell clones were isolated from cultures
transfected with pCR3.1 plasmids carrying either codon-
optimized CDNF or KTEL-deleted codon-optimized CDNF.
Altogether 5 or 9 out of total 10 isolated clones transfected
Figure 2. Microencapsulated wtCDNF ARPE-19 cell clones are viable but the secretion of CDNF decreases with time. (a) APA-
microcapsules with cell density of 2 million cells/ml of alginate. Scale bar 100 mm. (b) A density histogram showing the size distribution
of the prepared microcapsules. Mean capsule diameter for all the produced capsules was 169+ 26 mm (range 99–222 mm). (c) Cells stained
with LIVE/DEAD kit. Most of the encapsulated cells stained with calcein (live, green), and only a few with ethidium homodimer-1 (dead, red),
implying that the cells survived the encapsulation procedure well. (d) Viability test using resazurin solution (Alamar Blue reagent) shows
steady metabolic function of the encapsulated cells. (e) wtCDNF release measured in the conditioned media of encapsulated cells analyzed
on CDNF ELISA.
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with optiCDNF or optiCDNF-KTELdel, respectively,
secreted sufficient CDNF. CDNF secretion was on average
0.81 + 0.33 ng/0.4106 cells/30 min (min–max: 0.07–1.81
ng/0.4106 cells/30 min) in the case of optiCDNF, and 1.75
+ 0.44 ng/0.4106 cells/30 min (min–max: 0.30–4.88 ng/
0.4106/30 min) in the case of optiCDNF-KTELdel.
The secretion of CDNF from the KTEL-deleted codon-
optimized CDNF clones remained stable in cultures held
Table 2. CDNF Concentrations Analyzed by ELISA in the Conditioned Media and Cell Lysates After Transient Transfection of ARPE-19
Cells. Cells Were Transfected with Empty Expression Vector, Vector Carrying Wild Type CDNF (wtCDNF), Codon-Optimized CDNF
(optiCDNF), KTEL-Deleted CDNF (CDNF-KTELdel), or KTEL-Deleted Codon-Optimized CDNF (optiCDNF-KTELdel). All Sequences
were Cloned Into pCR3.1 Transfection Vector.
Empty vector wtCDNF optiCDNF CDNF- KTELdel optiCDNF-KTELdel
CDNF in medium (ng/ml) n.d. 142.1 474.6 409.3 687.2
CDNF in cells (ng/ml) 0.5 1566.1 2956.5 442.4 574.9
Times secreted vs. wtCDNF 1 3.3 2.9 4.8
Times intracellular vs. wtCDNF 1 1.9 0.3 0.4
% secreted 0 8.3 13.8 48.1 54.4
n.d. ¼ not detected.
Figure 3. Codon optimization and deletion of the putative ER-retrieval signal (KTEL) increases the CDNF secretion. (a) Immunoblot
showing increased CDNF secretion with the modified CDNF constructs, and lower intracellular protein amount in case of KTEL deletion.
Samples were collected 48 h after transient transfection of ARPE-19 cells with empty expression vector, vector with wild type CDNF
(wtCDNF), KTEL-deleted CDNF (CDNF-KTELdel), codon-optimized CDNF (optiCDNF), or KTEL-deleted codon-optimized CDNF
(optiCDNF-KTELdel). (b) Epifluorescent microscope images on ARPE-19 cells double stained with anti-CDNF and anti-PDI or GM130,
for the detection of ER and Golgi apparatus, respectively. Images were captured using same exposure times. The cells were transfected
either with wild type CDNF (wtCDNF) or KTEL-deleted CDNF (CDNF-KTELdel).
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without sub-cultivation for up to 14 days. The observed
secretion of optiCDNF-KTELdel was 99.1 + 5.9%, 97.9
+ 5.3%, and 99.4 + 5.0% (p¼0.95, repeated measures
ANOVA, n¼8) from the initial secreted amounts at days 4,
7, and 14 from sub-cultivation, respectively (Fig. 4a). The
secretion of optiCDNF was 65.0+ 9.0%, 40.7+ 20.5% and
42.2 + 14.6% (p¼0.46, n¼4) at the same time points. For
reference, CDNF secretion from wtCDNF-expressing clones
was 18.5+ 4.4% (p<0.001, n¼11) at 7 and 14 days from the
initial secretion.
When the confluent ARPE-19 clones were divided after 14
days without sub-cultivation, the secreted CDNF amount
increased 4-fold from 0.13 + 0.05% to 0.55 + 0.07% of
total CDNF (p¼0.005, paired samples t-test, n¼5, Fig. 4b)
in clones overexpressing wtCDNF. The observed CDNF
secretion from optiCDNF cell clones increased 2-fold, but the
difference was statistically insignificant (from 0.47 + 0.20%
to 0.93 + 0.11%, p¼0.094, n¼3). No increase of CDNF
secretion was observed in the case of optiCDNF-KTELdel
cell clones (6.19 + 0.57% vs. 6.54 + 1.22%, p¼0.77, n¼3).
Discussion
In this study, we have produced several CDNF-
overexpressing ARPE-19 cell clones for the purpose of
encapsulated cell therapy. Intracellular endogenous CDNF
was detected in the parental ARPE-19 cell line, but no
CDNF was found in the conditioned medium. Likewise,
secreted endogenous CDNF was not found in any of the
other four tested cell lines, although all cell lines expressed
CDNF. In contrast, endogenous MANF was found in the
conditioned media of all the cell lines. The level of endo-
genous human CDNF and MANF secretion has not previ-
ously been compared. However, in the overexpression
situation Flag-tagged mouse CDNF and MANF were
secreted at a comparative level23. Because the intracellular
concentration of endogenous MANF was approximately 200
times higher than that of CDNF in the cell lines analyzed, the
absence of CDNF in the media could be explained by limited
ELISA sensitivity. As the measured concentration of MANF
in the medium samples was up to 4000 pg/ml, CDNF
secreted at the same proportion (appr. 20 pg/ml) would not
be detected with the used ELISA (sensitivity 30.5 pg/ml).
The poor secretion can also be a biological characteristic
of CDNF, as we encountered challenges in the secretion of
wtCDNF in overexpressing ARPE-19 clones as well. Only a
minor portion of the synthetized CDNF was secreted, while
most of the CDNF remained within the cells. Intracellular
CDNF concentration in the clones was increased up to 1800-
fold when compared with the endogenous CDNF concentra-
tion in the parental ARPE-19 cell line. The secretion of
wtCDNF decreased further when the clones were in a non-
dividing state. The same was observed in all wtCDNF-
expressing cell clones growing as a monolayer, as well as
in alginate capsules, in which the cells are unable to divide
due to contact-inhibited growth14. This is in sharp contrast to
overexpression of ciliary neurotrophic factor (CNTF)19 or
nerve growth factor (NGF)20 in the same cell line, where a
stable level of secreted transgene was observed for months in
non-dividing cells after encapsulation.
CDNF secretion from the cell clones was found to
increase after sub-cultivation. As the expression cassette is
integrated into the cellular genome in the stable cell clones,
this could be a consequence of quiescent chromatin status in
Figure 4. Secretion of KTEL-deleted codon-optimized CDNF is
stable in clones cultured on Petri dish. (a) The secretion of KTEL-
deleted codon-optimized CDNF was stable for 14 days in non-
subcultivated cell cultures. In contrast, the secretion of wtCDNF
decreased during the time course in cell cultures, which were not
subcultivated during the experiment (p<0.001, repeated measures
ANOVA with Bonferroni correction post hoc). (b) Secreted por-
tion of CDNF during 1 h incubation from the total expressed
CDNF (CDNF concentration in the medium þ cell lysate) was
similar in case of subcultivated and non-subcultivated clones
expressing KTEL-deleted codon-optimized CDNF. Instead, the
secreted portion of wtCDNF increased in the subcultivated cells
(p¼0.005, paired samples t-test). Data are presented as mean +
SEM. *** p<0.001, ** p<0.01.
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the non-dividing cells. When the cell division is triggered,
expression of the genome-integrated transgene can be reac-
tivated. However, two aspects argue against this. First, the
expression cassette also contains a neomycin resistance gene
allowing for positive selection with the presence of selection
antibiotic, which was present in the culture medium all the
time. This means that the neomycin resistance gene was
expressed all the time from the genomic location where
CDNF cDNA was inserted. Second, the intracellular CDNF
amount in the non-dividing cells was not decreased in the
non-dividing wtCDNF ARPE-19 clones. Thus, the clones
most likely continued to express CDNF, but its secretion was
inhibited.
The observations that intracellular CDNF resided within
the ER of the ARPE-19 clones and that the clones secreted
only minor amounts of the expressed transgene could indi-
cate that the ER of the cell clones was not functioning prop-
erly. However, in the case of CDNF, cell retention may be
caused by an ER-retrieval sequence, the C-terminal amino
acids: KTEL. The KTEL sequence is recognized by KDEL
receptors locating at the Golgi apparatus and retrieved back
to the ER24. Also in the case of MANF, the four last amino
acids (RTDL, in humans) bind to KDEL receptors25, and the
deletion of C-terminal RTDL increases MANF secretion, as
shown in vitro in multiple cell lines25–27. The same has been
shown for mouse and rat CDNF with the deletion of the
C-terminal QTEL23,28.
Under transient transfections, human CDNF secretion
was enhanced up to 3-fold when the putative ER-retrieval
sequence was deleted. The KTEL-deleted CDNF gave a
different staining pattern in immunocytochemistry com-
pared with the wtCDNF, indicating its localization to Golgi
apparatus as well as to the ER. The results imply that the ER-
retention of wtCDNF was caused, at least in part, by the
biological character of CDNF and not due to improper ER
function of the produced cell clones.
In addition to deleting the putative ER-retrieval signal,
we studied codon-optimized CDNF in relation to improved
CDNF secretion. In codon optimization, rare codons are
changed into more ubiquitously used ones without changing
the resultant amino acid that the codon stands for21. Thus,
the translated protein amount increases without any changes
in the resultant protein amino acid sequence. With codon
optimization, the CDNF secretion was enhanced up to 3-
fold, but the intracellular CDNF load increased 2-fold com-
pared with transfection with wtCDNF, which itself was
largely retained intracellularly. When combining both of the
methods, CDNF secretion increased up to 5-fold, and the
intracellular amount of KTEL-deleted codon-optimized
CDNF was only 40% from that of wtCDNF.
Additional cell clones were produced with plasmids car-
rying codon-optimized CDNF or KTEL-deleted codon-
optimized CDNF cDNA sequence. On average, the new
clones secreted 1.7 or 3.6 times more CDNF, respectively,
compared with the wtCDNF clones. More importantly, the
secretion of KTEL-deleted codon-optimized CDNF did not
decrease in confluent cultures, contrary to what was
observed in the case of wtCDNF and codon-optimized
CDNF. However, the biological activity of KTEL-deleted
CDNF is currently unknown. In the case of MANF, the
corresponding RTDL deletion did not abolish the neuropro-
tective effect of extracellularly administered MANF in a
stroke model in vivo27.
According to multiple studies performed on rodents1,4–9,
CDNF has potential in the treatment of Parkinson’s and
Alzheimer’s diseases. Continuous and de novo synthetized,
but retrievable, delivery of CDNF to the target site in the
brain can be achieved with polymer-encapsulated cells.
According to our results on ARPE-19 cells clones, the secre-
tion of wtCDNF is sub-optimal because it is highly retained
intracellularly, and its secretion is further decreased in non-
dividing cells. KTEL deletion improved both aspects, and
thus could be considered for the delivery of CDNF with
encapsulated cells. However, the in vivo biological activity
of the mutant protein has to be determined.
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